These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy. Ndembe G; Intini I; Moro M; Grasselli C; Panfili A; Panini N; Bleve A; Occhipinti M; Borzi C; Garassino MC; Marabese M; Canesi S; Scanziani E; Sozzi G; Broggini M; Ganzinelli M J Exp Clin Cancer Res; 2024 Jan; 43(1):6. PubMed ID: 38163906 [TBL] [Abstract][Full Text] [Related]
4. Targeting adhesion signaling in Gilbert-Ross M; Konen J; Koo J; Shupe J; Robinson BS; Wiles WG; Huang C; Martin WD; Behera M; Smith GH; Hill CE; Rossi MR; Sica GL; Rupji M; Chen Z; Kowalski J; Kasinski AL; Ramalingam SS; Fu H; Khuri FR; Zhou W; Marcus AI JCI Insight; 2017 Mar; 2(5):e90487. PubMed ID: 28289710 [TBL] [Abstract][Full Text] [Related]
5. Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden. Salehi-Rad R; Li R; Tran LM; Lim RJ; Abascal J; Momcilovic M; Park SJ; Ong SL; Shabihkhani M; Huang ZL; Paul M; Shackelford DB; Krysan K; Liu B; Dubinett SM Cancer Immunol Immunother; 2021 Aug; 70(8):2389-2400. PubMed ID: 33507343 [TBL] [Abstract][Full Text] [Related]
6. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer. Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500 [TBL] [Abstract][Full Text] [Related]
7. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Skoulidis F; Byers LA; Diao L; Papadimitrakopoulou VA; Tong P; Izzo J; Behrens C; Kadara H; Parra ER; Canales JR; Zhang J; Giri U; Gudikote J; Cortez MA; Yang C; Fan Y; Peyton M; Girard L; Coombes KR; Toniatti C; Heffernan TP; Choi M; Frampton GM; Miller V; Weinstein JN; Herbst RS; Wong KK; Zhang J; Sharma P; Mills GB; Hong WK; Minna JD; Allison JP; Futreal A; Wang J; Wistuba II; Heymach JV Cancer Discov; 2015 Aug; 5(8):860-77. PubMed ID: 26069186 [TBL] [Abstract][Full Text] [Related]
8. G6PD Maintains Redox Homeostasis and Biosynthesis in LKB1-Deficient KRAS-Driven Lung Cancer. Lan T; Arastu S; Wang S; Lam J; Wang W; Bhatt V; Lopes EC; Hu Z; Sun M; Luo X; Ghergurovich JM; Li C; Su X; Rabinowitz JD; White E; Guo JY bioRxiv; 2023 Oct; ():. PubMed ID: 37873106 [TBL] [Abstract][Full Text] [Related]
9. Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Talwelkar SS; Nagaraj AS; Devlin JR; Hemmes A; Potdar S; Kiss EA; Saharinen P; Salmenkivi K; Mäyränpää MI; Wennerberg K; Verschuren EW Mol Cancer Ther; 2019 Oct; 18(10):1863-1874. PubMed ID: 31320402 [TBL] [Abstract][Full Text] [Related]
10. PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer. Long LL; Ma SC; Guo ZQ; Zhang YP; Fan Z; Liu LJ; Liu L; Han DD; Leng MX; Wang J; Guo XJ; Tan JL; Cai XT; Lin Y; Pan X; Wu DH; Bai X; Dong ZY Cancer Res; 2023 Feb; 83(4):568-581. PubMed ID: 36512628 [TBL] [Abstract][Full Text] [Related]
12. CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer. Zhang M; Yang W; Wang P; Deng Y; Dong YT; Liu FF; Huang R; Zhang P; Duan YQ; Liu XD; Lin D; Chu Q; Zhong B Nat Commun; 2020 Nov; 11(1):6119. PubMed ID: 33257678 [TBL] [Abstract][Full Text] [Related]
13. Snail acetylation by autophagy-derived acetyl-coenzyme A promotes invasion and metastasis of KRAS-LKB1 co-mutated lung cancer cells. Han JH; Kim YK; Kim H; Lee J; Oh MJ; Kim SB; Kim M; Kim KH; Yoon HJ; Lee MS; Minna JD; White MA; Kim HS Cancer Commun (Lond); 2022 Aug; 42(8):716-749. PubMed ID: 35838183 [TBL] [Abstract][Full Text] [Related]
15. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation. Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S Front Immunol; 2022; 13():974581. PubMed ID: 36159860 [TBL] [Abstract][Full Text] [Related]
16. Targeting the ERβ/HER Oncogenic Network in Almotlak AA; Farooqui M; Soloff AC; Siegfried JM; Stabile LP Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008514 [TBL] [Abstract][Full Text] [Related]
17. KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma. Gao G; Liao W; Ma Q; Zhang B; Chen Y; Wang Y Lung Cancer; 2020 Nov; 149():41-45. PubMed ID: 32956987 [TBL] [Abstract][Full Text] [Related]